The patent, issued in Australia, covers Thymosin Beta 4, its analogues, isoforms and other derivatives and expires in 2022.
Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. RegeneRx is also developing RGN-457 for use in pulmonary indications such as cystic fibrosis.